Actinomycin D inhibits liver cancer invasion and metastasis by suppressing the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition

<x>Abstract</x> <sec> <title>Objective:</title> To investigate actinomycin D’s effects on liver cancer progression, explore its underlying mechanisms, focusing on epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling, offer new insights and references for identifying low toxicity traditional Chinese medicine (TCM) monomers with the same targets but lower toxicity or developing compound formulations to enhance pathway blocking effects, and to innovate and develop integrated Chinese and western medicine treatment strategies. </sec> <sec> <title>Methods:</title> Human liver cancer cells (HepG2) were treated with actinomycin D for <italic>in vitro</italic> assays. Cell proliferation was assessed <italic>via</italic> CCK-8, while transwell assays evaluated invasion and migration. Western blot analyzed expression of EMT markers (E-cadherin, β-catenin, Twist1). A nude mouse metastatic model using HepG2 cells was established for <italic>in vivo</italic> validation, with metastasis efficiency and molecular markers compared between treatment and control groups. </sec> <sec> <title>Results:</title> Actinomycin D suppressed liver cancer cell proliferation in a dose-dependent and time-dependent manner (CCK-8 assay) and inhibited cell invasion and migration (assessed by transwell assay). Western blot analysis showed that actinomycin D downregulated β-catenin and Twist1 while upregulating E-cadherin, indicating suppression of EMT. <italic>In vivo</italic> experiments demonstrated that actinomycin D significantly reduced metastatic efficiency in mice, consistent with decreased β-catenin/Twist1 expression and increased E-cadherin levels in tumor tissues. </sec> <sec> <title>Conclusions:</title> Actinomycin D suppresses liver cancer invasion and metastasis by inhibiting the Wnt/β-catenin pathway and EMT progression. These findings highlight its dual antitumor role in both proliferation inhibition and metastasis suppression, providing mechanistic insights for its clinical applications. </sec>

Authors

Publication Details

Journal
World Journal of Integrated traditional and western Medicine(WJIM)
Published
2024-12-01
DOI
https://doi.org/10.70976/j.2096-0964.wjim-2024-0026
Primary Topic
Peptidase Inhibition and Analysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Actinomycin D inhibits liver cancer invasion and metastasis by suppressing the Wnt/&beta;-catenin signaling pathway and epithelial-mesenchymal transition

Cho Wing Li, Liang Chen, Qinghua Lu, Yi-Long Lung Cancer Wu et al.
World Journal of Integrated traditional and western Medicine(WJIM)
Peptidase Inhibition and Analysis
article

Actinomycin D inhibits liver cancer invasion and metastasis by suppressing the Wnt/&beta;-catenin signaling pathway and epithelial-mesenchymal transition

Cho Wing Li, Liang Chen, Qinghua Lu, Yi-Long Lung Cancer Wu, Yaping Sun
article en

Abstract

<x>Abstract</x> <sec> <title>Objective:</title> To investigate actinomycin D’s effects on liver cancer progression, explore its underlying mechanisms, focusing on epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling, offer new insights and references for identifying low toxicity traditional Chinese medicine (TCM) monomers with the same targets but lower toxicity or developing compound formulations to enhance pathway blocking effects, and to innovate and develop integrated Chinese and western medicine treatment strategies. </sec> <sec> <title>Methods:</title> Human liver cancer cells (HepG2) were treated with actinomycin D for <italic>in vitro</italic> assays. Cell proliferation was assessed <italic>via</italic> CCK-8, while transwell assays evaluated invasion and migration. Western blot analyzed expression of EMT markers (E-cadherin, β-catenin, Twist1). A nude mouse metastatic model using HepG2 cells was established for <italic>in vivo</italic> validation, with metastasis efficiency and molecular markers compared between treatment and control groups. </sec> <sec> <title>Results:</title> Actinomycin D suppressed liver cancer cell proliferation in a dose-dependent and time-dependent manner (CCK-8 assay) and inhibited cell invasion and migration (assessed by transwell assay). Western blot analysis showed that actinomycin D downregulated β-catenin and Twist1 while upregulating E-cadherin, indicating suppression of EMT. <italic>In vivo</italic> experiments demonstrated that actinomycin D significantly reduced metastatic efficiency in mice, consistent with decreased β-catenin/Twist1 expression and increased E-cadherin levels in tumor tissues. </sec> <sec> <title>Conclusions:</title> Actinomycin D suppresses liver cancer invasion and metastasis by inhibiting the Wnt/β-catenin pathway and EMT progression. These findings highlight its dual antitumor role in both proliferation inhibition and metastasis suppression, providing mechanistic insights for its clinical applications. </sec>

World Journal of Integrated traditional and western Medicine(WJIM)Vol. 10(4)
Good health and well-being
Openalex Percentile: Top 57%
Peptidase Inhibition and Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.